var data={"title":"Vancomycin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vancomycin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7141?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vancomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vancomycin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vancomycin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50667383\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Intraocular Injection Safety Review</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has concluded that the <i>prophylactic</i> use of intraocular vancomycin, alone or in a compounded drug combining multiple active ingredients, during cataract surgery is generally not recommended because of the risk of hemorrhagic occlusive retinal vasculitis (HORV). The FDA recently received an adverse event report concerning a patient who was diagnosed postoperatively with bilateral HORV after being administered injections of Imprimis Pharmaceuticals' compounded triamcinolone, moxifloxacin, and vancomycin formulation in each eye at the conclusion of cataract surgery procedures that were performed 2 weeks apart. The FDA is unaware of any adequately controlled studies demonstrating the safety and efficacy of intraocular vancomycin in preventing endophthalmitis. There is no FDA-approved vancomycin formulation for intraocular injection.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm578743.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPG6jnWVdkJ4rlHSePh6VTLmOhyJ+Nznygvd8P/bvekGQX5dujULjGxVyhOXYIw1Bh9i85TeA+aP+CDg+ZuBgVnneL0HZBXiJJDMfSFPo4jLgBp450LotoVT6T/Z3ONRAnA==&amp;TOPIC_ID=10037\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm578743.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233330\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>First-Vancomycin 25;</li>\n      <li>First-Vancomycin 50;</li>\n      <li>Firvanq;</li>\n      <li>Vancocin HCl;</li>\n      <li>Vancomycin+SyrSpend SF PH4</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233331\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vancocin;</li>\n      <li>Vancomycin Hydrochloride for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233378\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Glycopeptide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233334\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> <b>Note:</b> Initial IV dosing in nonobese patients should be based on actual body weight; subsequent dosing should generally be adjusted based on serum trough vancomycin concentrations and renal function. Patient-specific pharmacokinetic calculations may be needed to determine appropriate dose and interval in patients expected to have altered pharmacokinetics (eg, morbid obesity, burns, critical illness, unstable renal function, pregnancy, cystic fibrosis). For patients with uncomplicated skin and soft tissue infections who are not obese and have normal renal function, serum trough monitoring is generally not needed (IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Note:</b> Ineffective for treating <i>C. difficile</i> infections (CDIs): 15 to 20 mg/kg/dose (rounded to the nearest 250 mg; usual maximum: 2 g/dose initially) every 8 to 12 hours (ASHP/IDSA/SIDP [Rybak 2009]). <b>Note:</b> 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours is a usual starting dose in most nonobese patients with normal renal function; refer to infection-specific dosing (Drew 2017; IDSA [Liu 2011]; Murray 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Loading dose:</i> Complicated infections in seriously ill patients: A loading dose of 25 to 30 mg/kg (based on actual body weight) may be used to rapidly achieve target concentrations (ASHP/IDSA/SIDP [Rybak 2009]; Reardon 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: <b>Note:</b> Ineffective for treating systemic infections: 125 to 500 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacteremia (</b>\n      <b>off-label dose): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Empiric therapy or pathogen-specific therapy for methicillin-resistant S. aureus:</i> IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL. A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]). For catheter-related bloodstream infections, consider antibiotic lock therapy for catheter salvage, in addition to systemic therapy (IDSA [Mermel 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Empiric therapy or pathogen-specific therapy for methicillin-resistant coagulase-negative staphylococci:</i> IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours (most patients with normal renal function can be started with 15 mg/kg/dose every 12 hours); adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (Drew 2017). For catheter-related bloodstream infections, consider antibiotic lock therapy for catheter salvage, in addition to systemic therapy (IDSA [Mermel 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Antibiotic lock technique</i> (catheter salvage strategy (off-label use): Prepare lock solution to final concentration of vancomycin 5 mg/mL (may be combined with heparin 5,000 units/mL). Instill into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL) with a dwell time of 48 to 72 hours. Dwell times will depend on frequency of catheter use. Withdraw lock solution prior to catheter use; replace with fresh vancomycin lock solution after catheter use. For catheter-related bloodstream infections consider antibiotic lock technique, in addition to systemic antibiotics. Duration of lock therapy should be 10 to 14 days (IDSA [Mermel 2009]; LaPlante 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain abscess, intracranial or spinal epidural abscess</b>\n      <b> (off-label dose): As a component of empiric therapy or pathogen specific therapy for methicillin-resistant <i>S. aureus</i>: </b> IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL. A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cerebrospinal fluid (CSF) shunt infection (off-label use): </b>\n      <b>As a component of</b> <b>empiric therapy or pathogen-specific therapy (eg, methicillin-resistant </b><i><b>S. aureus</b></i><b> or coagulase-negative staphylococci</b><b>):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (IDSA [Tunkel 2017]). A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intraventricular (adjunct to systemic therapy; use a preservative-free preparation): 5 to 20 mg; adjust dosage and administration interval based on CSF vancomycin concentrations (goal: 10 to 20 times MIC of causative organism), ventricular size, and daily output from ventricular drain. When intraventricular vancomycin is administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in CSF) (IDSA [Tunkel 2004; Tunkel 2017]). <b>Note:</b> Intraventricular administration is generally reserved for use in patients who fail parenteral therapy despite removal of CSF shunt or when CSF shunt cannot be removed (Baddour 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Clostridium difficile</i> infection (CDI)</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild or moderate CDI:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial episode or first relapse: 125 mg 4 times daily for 10 to 14 days (AHRQ [Butler 2016]; Kelly 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Second relapse: Pulsed and/or tapered therapy over 6 to 7 weeks (Kelly 2017; SHEA/IDSA [Cohen 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe, complicated CDI: 125 to 500 mg 4 times daily (ACG [Surawicz 2013]; ESCMID [Debast 2014]; SHEA/IDSA [Cohen 2010])]; with or without IV metronidazole (Rokas 2015). Vancomycin retention enema may be added if there is concern that orally administered vancomycin may not reach colon (ACG [Surawicz 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal (intracolonic) (off-label route): Retention enema: <b>Note: </b>Institution-specific protocols vary; optimal regimen not established. Consider assessing serum concentration as absorption may occur through inflamed mucosa (SHEA/IDSA [Cohen 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe, complicated infection in patients with a condition that may prevent oral vancomycin from reaching the colon (eg, ileus, megacolon, ileostomy) or unable to tolerate oral therapy: 500 mg every 6 hours (in 100 mL NS) (SHEA/IDSA [Cohen 2010]) retained for 1 hour (Apisarnthanarak 2002), with oral vancomycin (if tolerated) with or without concurrent IV metronidazole; dose adjustment and/or altered volume (eg, up to 500 mL NS) may be needed based upon extent of disease and patient weight (ACG [Surawicz 2013]; SHEA/IDSA [Cohen 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus (native or prosthetic valve; penicillin-resistant strains or patients unable to tolerate beta-lactams):</i> IV: 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours in combination with gentamicin for 6 weeks; adjust dose to obtain a trough concentration of 10 to 20 mcg/mL (AHA [Baddour 2015]); some experts favor a trough of 15 to 20 mcg/mL (BSAC [Gould 2012]; ESC [Habib 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>S. aureus, methicillin-resistant or methicillin-susceptible (severe-beta lactam hypersensitivity; alternative agent):</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Native valve: 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours for 6 weeks; dose adjusted to obtain a serum trough concentration of 10 to 20 mcg/mL (AHA [Baddour 2015]) <b>or</b> 15 to 20 mg/kg/dose (usual maximum dose: 2 g/dose initially) every 8 to 12 hours for 6 weeks; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (IDSA [Lui 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prosthetic valve: 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours; adjust dose to obtain a trough concentration of 10 to 20 mcg/mL (AHA [Baddour 2015]) <b>or</b> 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (IDSA [Lui 2011]). Duration of therapy: At least 6 weeks (combine with rifampin for the entire duration of therapy and gentamicin for the first 2 weeks) (AHA [Baddour 2015]; IDSA [Lui 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Viridans group Streptococcus and S. bovis (native or prosthetic valve; penicillin or ceftriaxone intolerance):</i> IV: 15 mg/kg/dose (usual maximum dose: 2 g/dose initially) every 12 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve); adjust dose to obtain a trough concentration of 10 to 15 mcg/mL (AHA [Baddour 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endophthalmitis, treatment (off-label use):</b> Intravitreal: Usual dose: 1 mg/0.1 mL NS or sterile water injected into vitreum, usually in combination with ceftazidime (Durand 2017; Kelsey 1995). May repeat after 48 hours if needed based on culture result (Durand 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Group B streptococcus (neonatal prophylaxis) (off-label use; alternative agent):</b> IV: 20 mg/kg (maximum: 2 g/dose) every 8 hours from onset of labor until delivery (Onwuchuruba 2014). <b>Note:</b> Reserved for penicillin allergic patients at high risk for anaphylaxis and if organism is resistant to clindamycin or when no susceptibility data are available (CDC 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection (off-label use): As a component of empiric therapy or pathogen-specific therapy (eg, methicillin-resistant <i><b>S. aureus</b></i><b>): </b></b>IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis, bacterial (off-label use):</b> <b>As a component of</b> <b>empiric therapy or pathogen-specific therapy (eg, methicillin-resistant </b><i><b>S. aureus </b></i><b>or penicillin- and cephalosporin-resistant <i>S. pneumoniae</i>): </b>IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (IDSA [Tunkel 2004; 2017]) A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis</b>\n      <b> (off-label dose):</b> <b> As a component of empiric therapy or pathogen-specific therapy (eg, methicillin-resistant <i>S. aureus</i>): </b>IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours (IDSA [Liu 2011]) <b>or</b> 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours (IDSA [Berbari 2015]); adjust dose to obtain a trough concentration of 15 to 20 mcg/mL. A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative prophylaxis (in combination with other appropriate agents when coverage for methicillin-resistant <i>S. aureus </i>is indicated or for gram-positive coverage in patients unable to tolerate beta-lactams) (off-label use): </b>IV: 15 mg/kg (usual maximum: 2 g/dose initially) started within 60 to 120 minutes prior to initial surgical incision. Vancomycin doses may be repeated intraoperatively in 2 half-lives (approximately 8 to 12 hours in patients with normal renal function) if procedure is lengthy or if there is excessive blood loss (ASHP/IDSA/SIS/SHEA [Bratzler 2013]). In cases where an extension of prophylaxis is warranted post-operatively, total duration should be &le;24 hours (Anderson 2014). <b>Postoperative</b> prophylaxis is not recommended in clean and clean-contaminated surgeries (CDC [Berrios-Torres 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritonitis, treatment (continuous ambulatory dialysis [CAPD] patients) (off-label use):</b> Intraperitoneal: <b>Note:</b> Intraperitoneal administration is preferred to IV administration. Adjust dose to obtain a trough concentration between 15 and 20 mcg/mL (ISPD [Li 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent (preferred): 15 to 30 mg/kg added to one exchange of CAPD solution every 5 to 7 days (allow to dwell for &ge;6 hours); supplemental doses and more frequent monitoring of serum levels may be needed for patients receiving automated peritoneal dialysis (APD) or with significant residual renal function (ISPD [Li 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous (all exchanges): Loading dose: 30 mg/kg added to first exchange of CAPD solution; maintenance dose: 1.5 mg/kg/bag for each subsequent exchange of CAPD solution (Bunke 1983; ISPD [Li 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia</b>, <i>S. aureus</i> (methicillin-resistant): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Community-acquired pneumonia (CAP) (hospitalized patient): As a component of empiric therapy or pathogen-specific therapy for community-acquired methicillin-resistant S. aureus: </i>15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]; IDSA [Mandell 2007]); most patients with normal renal function can be started with 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours. Adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (File 2017). A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]; IDSA [Mandell 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP):</i> As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant <i>S.</i> <i>aureus</i>: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL. A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]; ATS/IDSA [Kalil 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pathogen-specific therapy for methicillin-resistant or susceptible S. aureus (alternative agent in beta-lactam intolerance):</i> IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours (Berbari 2017; IDSA [Liu 2011]) <b>or </b>15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours (IDSA [Osmon 2013]); adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (ASHP/IDSA/SIDP [Rybak 2009]). <b> Note:</b> May be combined with oral rifampin in selected cases (eg, debridement and retention of prosthesis or one-stage arthroplasty).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pathogen-specific therapy for Enterococcus</i> <i>spp (penicillin susceptible [alternative agent] or penicillin resistant)</i>: 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours (Berbari 2017; IDSA [Osmon 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sepsis/septic shock (off-label dose):</b> <b>As a component of empiric therapy or pathogen-specific therapy of methicillin-resistant <i>S. aureus</i><b>:</b></b> IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (ASHP/IDSA/SIDP [Rybak 2009]). Administer within 1 hour of identifying sepsis (Rhodes 2017). A loading dose may be considered in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]; Rhodes 2017). A duration of therapy of 7 to 10 days is generally adequate for serious infections; a variety of factors play a role in determining optimal duration of therapy (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic arthritis, without prosthetic material (off-label dose):</b> <b>As a component of empiric therapy or pathogen-specific therapy of methicillin-resistant <i>S. aureus</i> or coagulase-negative staphylococci: </b>IV: 15 to 20 mg/kg/dose (usual maximum: 2 g/dose initially) every 8 to 12 hours; adjust dose to obtain a trough concentration of 15 to 20 mcg/mL (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]). Most patients with normal renal function can be started with 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours (Goldenberg 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections (hospitalized patient) (off-label dose): As a component of empiric therapy or pathogen-specific therapy of methicillin-resistant <i>S. aureus</i>:</b> IV: 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours (IDSA [Stevens 2014]); adjust dose to obtain a trough concentration of 10 to 15 mcg/mL (uncomplicated infection) or 15 to 20 mcg/mL (complicated infection or seriously ill) (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]; IDSA [Stevens 2014]). <b>Note:</b> For empiric therapy of necrotizing infection, must be used in combination with other agents (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infections (off-label use):</b> <b>As a component of empiric therapy or pathogen-specific therapy of methicillin-resistant <i>S.</i><i>aureus</i>: </b>IV: 15 mg/kg/dose (usual maximum: 2 g/dose initially) every 12 hours; adjust dose to obtain trough concentrations of 10 to 15 mcg/mL (uncomplicated infection) or 15 to 20 mcg/mL (complicated infections or seriously ill) (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Stevens 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233358\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vancomycin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> <b>Note:</b> Initial IV dosing should be based on actual body weight; subsequent dosing adjusted based on serum trough vancomycin concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Infants &gt;2 months (60 days), Children, and Adolescents</i> (<i>Red Book [AAP 2015]):</i> <b>Note:</b> Every 6 hour dosing recommended as initial dosage regimen if targeting trough serum concentrations &gt;10 mcg/mL (Benner 2009; Frymoyer 2009) in patients with normal renal function. Close monitoring of serum concentrations and assurance of adequate hydration status is recommended; utilize local antibiogram and protocols for further guidance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infection: IV: 40 to 45 mg/kg/<b>day</b> divided every 6 to 8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infection: IV: 45 to 60 mg/kg/<b>day</b> divided every 6 to 8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacteremia (</b>\n      <b>off-label use):</b> <b>Empiric therapy or pathogen-specific therapy (eg, methicillin-resistant <i>S. aureus</i>): </b>Children and Adolescents: IV: 15 mg/kg/dose every 6 hours for 2 to 6 weeks depending on severity (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain abscess, intracranial epidural abscess, spinal epidural abscess (</b>\n      <b>\n        <i>S. aureus</i></b>\n      <b> [methicillin-resistant]) (off-label use):</b> <b>As a component of empiric therapy or pathogen specific therapy for methicillin-resistant <i>S. aureus</i>: </b>Children and Adolescents: IV: 15 mg/kg/dose every 6 hours for 4 to 6 weeks (with or without rifampin) (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>C. difficile </i></b>\n      <b>infection (CDI):</b> Infants &gt;1 month, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> Oral: 40 mg/kg/day in 3 to 4 divided doses for 7 to 10 days (maximum: 2,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-positive patients:</i> Adolescents: Oral: 125 mg 4 times daily for 10 to 14 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Empiric therapy/culture negative:</i></b> Children and Adolescents: IV 60 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 2,000 mg/<b>day</b>; use in combination with other antibiotics for at least 4 weeks; longer duration may be required if prosthetic material is present; dosage should be adjusted to target trough serum concentrations of 10 to 15 mcg/mL; higher trough concentrations (15 to 20 mcg/mL) may be needed if there is a lack of response or if a resistant organism (MIC &gt;1 mcg/mL) is identified (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Streptococcus (including enterococcus):</i></b> Children and Adolescents: IV: 40 mg/kg/<b>day</b> divided every 8 to 12 hours for at least 4 to 6 weeks; a longer duration and additional antibiotics may be required depending on organism and presence of prosthetic material; dosage should be adjusted to target trough serum concentrations of 10 to 15 mcg/mL; higher trough concentrations (15 to 20 mcg/mL) may be needed for resistant organisms (MIC &gt;1 mcg/mL) or if there is a lack of response (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>S. aureus:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-methicillin resistant: Children and Adolescents: IV: 40 mg/kg/<b>day</b> divided every 8 to 12 hours for at least 4 to 6 weeks; a longer duration and additional antibiotics may be required depending on organism and presence of prosthetic material; dosage should be adjusted to target trough serum concentrations of 10 to 15 mcg/mL; higher trough concentrations (15 to 20 mcg/mL) may be needed for resistant organisms (MIC &gt;1 mcg/mL) or if there is a lack of response (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Methicillin-resistant:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AHA Guidelines: Children and Adolescents: IV: 40 mg/kg/<b>day</b> divided every 8 to 12 hours for at least 6 weeks; maximum daily dose: 2,000 mg/<b>day;</b> a longer duration may be required depending on the presence of prosthetic material; dosage should be adjusted to target trough serum concentrations of 15 to 20 mcg/mL (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IDSA Guidelines: Infants, Children, and Adolescents: IV: 60 mg/kg/<b>day</b> divided every 6 hours (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis, bacterial:</b> Infants &gt;1 month, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours (for empiric therapy, use in combination with a third-generation cephalosporin); duration of therapy should be individualized based upon clinical response (in general, 10 to 21 days) (IDSA [Tunkel 2004]). For methicillin-resistant <i>S. aureus</i>, treat for 2 weeks (with or without rifampin) (IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis (</b>\n      <b>off-label use):</b> <b>As a component of</b> <b>empiric therapy or pathogen-specific therapy (eg, methicillin-resistant <i>S. aureus</i>): </b>Children and Adolescents: IV: 15 mg/kg/dose every 6 hours for 4 to 6 weeks (IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative prophylaxis (off-label use):</b> Children and Adolescents: IV: 15 mg/kg/dose within 120 minutes prior to surgical incision. May be administered in combination with other antibiotics depending upon the surgical procedure (ASHP/IDSA/SIS/SHEA [Bratzler 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>For patients known to be colonized with methicillin-resistant <i>S. aureus</i>, a single 15 mg/kg preoperative dose may be added to other recommended agents for the specific procedure (ASHP/IDSA/SIS/SHEA [Bratzler 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):</i> Infants &gt;3 months, Children, and Adolescents: IV: <b>Note:</b> In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out. Also consider if community-acquired MRSA suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Group A <i>Streptococcus</i> (alternative to ampicillin or penicillin in beta-lactam allergic patients): 40 to 60 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Presumed bacterial (in addition to recommended antibiotic therapy), <i>S. pneumoniae</i>, moderate to severe infection (MICs to penicillin &le;2.0 mcg/mL) (alternative to ampicillin or penicillin): 40 to 60 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i> (methicillin-susceptible) (alternative to cefazolin/oxacillin): 40 to 60 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i>, moderate to severe infection (methicillin-resistant +/- clindamycin susceptible) (preferred): 40 to 60 mg/kg/day divided every 6 to 8 hours <b>or</b> dosing to achieve AUC/MIC &gt;400</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate regimen: 60 mg/kg/day divided every 6 hours for 7 to 21 days, depending on severity (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae</i>, moderate to severe infection (MICs to penicillin &ge;4.0 mcg/mL) (alternative to ceftriaxone in beta-lactam allergic patients): 40 to 60 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Health care&ndash;associated pneumonia (HAP): </i>As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant<i><i>S.</i><i>aureus</i>:</i> Infants, Children, and Adolescents: IV: 60 mg/kg/day divided every 6 hours for 7 to 21 days depending on severity (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against infective endocarditis:</b> Children and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dental, oral, or upper respiratory tract surgery: 20 mg/kg/dose administered 1 hour prior to the procedure. <b>Note:</b> American Heart Association (AHA) guidelines recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GI/GU procedure: 20 mg/kg (plus gentamicin 1.5 mg/kg) administered 1 hour prior to surgery. <b>Note:</b> Routine prophylaxis no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic arthritis (off-label use):</b> <b>As a component of empiric therapy or pathogen-specific therapy of methicillin-resistant <i>S. aureus</i>: </b>Children and Adolescents: IV: 15 mg/kg/dose every 6 hours for minimum of 3 to 4 weeks (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections, complicated (off-label use):</b> <b>As a component of empiric therapy or pathogen-specific therapy of methicillin-resistant <i>S. aureus</i>: </b>Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-necrotizing infection: 10 mg/kg/dose every 6 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Necrotizing infection: 15 mg/kg/dose every 6 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: <i>S. aureus</i> (methicillin-resistant): 60 mg/kg/day divided every 6 hours for 7 to 14 days (IDSA [Liu 2011])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233335\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233336\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>IV:</b> <b>Note: </b>Vancomycin levels should be monitored in patients with any renal impairment: In critically ill patients with renal insufficiency, the initial loading dose (~25 mg/kg) should not be reduced. However, subsequent dosage adjustments should be made based on renal function and trough serum concentrations (Wang 2001).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Vancomycin Initial Dosage Regimens for Patients With Impaired Renal Function (Golightly 2013)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">eGFR (mL/minute per 1.73 m<sup>2</sup>)</p></th>\n          <th colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Actual Body Weight</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;60 kg</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 80 kg</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">81 to 100 kg</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;100 kg</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>a</sup>Check a random vancomycin level in 24 hours after the dose. If random level is &le;20 mcg/mL, repeat the dose. If random level is &gt;20 mcg/mL, do not re-dose; repeat random level in 12 hours.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;90</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">750 mg every 8 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 8 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,250 mg every 8 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,500 mg every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 to 90</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">750 mg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,250 mg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 49</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">750 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,250 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,500 mg every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;15<sup>a</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">750 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,250 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,500 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Dialysis: </i>Poorly dialyzable by intermittent hemodialysis; however, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance, and generally requires replacement dosing (Launay-Vacher 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Following loading dose of 15 to 25 mg/kg, give either 500 to 1,000 mg <b>or</b> 5 to 10 mg/kg after each dialysis session (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Redosing based on pre-HD concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;10 mg/L: Administer 1,000 mg after HD</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">10 to 25 mg/L: Administer 500 to 750 mg after HD</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;25 mg/L: Hold vancomycin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Redosing based on post-HD concentrations: &lt;10 to 15 mg/L: Administer 500 to 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): 1 g every 4 to 7 days (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: Loading dose of 15 to 25 mg/kg, followed by either 1,000 mg every 48 hours <b>or</b> 10 to 15 mg/kg every 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD: Loading dose of 15 to 25 mg/kg, followed by either 1,000 mg every 24 hours <b>or</b> 10 to 15 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHDF: Loading dose of 15 to 25 mg/kg, followed by either 1,000 mg every 24 hours <b>or</b> 7.5 to 10 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Consider redosing patients receiving CRRT for vancomycin concentrations &lt;10 to 15 mg/L.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14320791\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Oral:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>IV: </b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, degrees of hepatic dysfunction do not affect the pharmacokinetics of vancomycin (Marti, 1996). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233306\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vancocin HCl: 125 mg, 250 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mg/100 mL in Dextrose 5% (100 mL); 1000 mg/150 mL in NaCl 0.9% (150 mL); 1000 mg/200 mL in Dextrose 5% (200 mL); 1000 mg/200 mL in NaCl 0.9% (200 mL); 1000 mg/250 mL in Dextrose 5% (250 mL); 1000 mg/250 mL in NaCl 0.9% (250 mL); 1250 mg/150 mL in NaCl 0.9% (150 mL); 1250 mg/250 mL in Dextrose 5% (250 mL); 1250 mg/250 mL in NaCl 0.9% (250 mL); 1500 mg/150 mL in NaCl 0.9% (150 mL); 1500 mg/250 mL in Dextrose 5% (250 mL); 1500 mg/250 mL in NaCl 0.9% (250 mL); 1500 mg/500 mL in Dextrose 5% (500 mL); 1500 mg/500 mL in NaCl 0.9% (500 mL); 1750 mg/250 mL in NaCl 0.9% (250 mL); 1750 mg/300 mL in NaCl 0.9% (300 mL); 1750 mg/500 mL in Dextrose 5% (500 mL); 1750 mg/500 mL in NaCl 0.9% (500 mL); 2000 mg/250 mL in NaCl 0.9% (250 mL); 2000 mg/500 mL in Dextrose 5% (500 mL); 2000 mg/500 mL in NaCl 0.9% (500 mL); 2500 mg/500 mL in NaCl 0.9% (500 mL); 500 mg/100 mL in Dextrose 5% (100 mL); 750 mg/150 mL in Dextrose 5% (150 mL); 750 mg/150 mL in NaCl 0.9% (150 mL); 750 mg/250 mL in NaCl 0.9% (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Vancomycin 25: 25 mg/mL (150 mL, 300 mL) [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Vancomycin 50: 50 mg/mL (150 mL, 210 mL, 300 mL) [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea [DSC]); 1000 mg (1 ea [DSC]); 5000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 750 mg (1 ea); 1000 mg (1 ea); 5000 mg (1 ea); 10 g (1 ea); 100 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Firvanq: 25 mg/mL (150 mL, 300 mL); 50 mg/mL (150 mL, 300 mL) [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vancomycin+SyrSpend SF PH4: 50 mg/mL (120 mL, 240 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233291\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040033\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">First-Vancomycin oral solution and Vancomycin+SyrSpend SF oral suspension are compounding kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51063159\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Firvanq (vancomycin powder for oral solution): FDA approved January 2018; availability anticipated April 2018. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233311\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravenous: Administer vancomycin with a final concentration not to exceed 5 mg/mL by IV intermittent infusion over at least 60 minutes (recommended infusion period of &ge;30 minutes for every 500 mg administered [ASHP/IDSA/SIDP (Rybak 2009)]); in adult patients in need of fluid restriction, a concentration up to 10 mg/mL may be used, but risk of infusion-related reactions is increased. Not for IM administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If a maculopapular rash appears on the face, neck, trunk, and/or upper extremities (red man syndrome), slow the infusion rate to over 1<sup>1</sup>/<sub>2</sub> to 2 hours and increase the dilution volume (Healy 1990; Rybak 1986; Szymusiak-Mutnick 1996). Hypotension, shock, and cardiac arrest (rare) have also been reported with too rapid of infusion. Administration of antihistamines prior to infusion may prevent or minimize this reaction (Rybak 1986; Wilhem 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Irritant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding the use of dry cold or dry warm compresses (Hurst 2004; Reynolds 2014); however, dry warm compresses may be of benefit in increasing local blood flow to enhance drug removal from the extravasation site (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antibiotic lock technique (off-label use): Instill prepared vancomycin lock solution into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL) with a dwell time of 48 to 72 hours (dependent on frequency of catheter use). Withdraw lock solution prior to catheter use; replace with fresh vancomycin lock solution after catheter use (IDSA [Mermel 2009]; LaPlante 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraventricular (off-label route): Use preservative-free preparations only. May be administered intraventricularly with a final concentration of 2.5 to 10 mg/mL for the treatment of CSF shunt infections. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow vancomycin solution to equilibrate in the CSF (IDSA [Tunkel 2004; Tunkel 2017]; Ng 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravitreal (off-label route): May administer vancomycin intravitreally with a final concentration of 1 mg/0.1 mL NS or sterile water (Durand 2017; Kelsey 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution (Firvanq): Shake reconstituted oral solution well before each use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Vancomycin powder for injection may be reconstituted and used for oral administration (SHEA/IDSA [Cohen 2010]). Reconstituted powder for injection (not premixed solution) may be administered orally by diluting the reconstituted solution in 30 mL of water; common flavoring syrups may be added to improve taste. The unflavored, diluted solution may also be administered via nasogastric tube. Also see Extemporaneously Prepared section.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal (off-label route): May be administered as a retention enema per rectum (SHEA/IDSA [Cohen 2010]); 500 mg in 100 to 500 mL of NS, volume may depend on length of segment being treated. If sodium chloride causes hyperchloremia could use solution with lower chloride concentration (eg, LR) (ACG [Surawicz 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233310\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Clostridium difficile</i> infection (oral): </b>Treatment of <i>C. difficile</i> infection (CDI)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis (injection):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Corynebacteria (diphtheroids): </i>Treatment of diphtheroid endocarditis in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by diphtheroids</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcal: </i>Treatment of endocarditis caused by enterococci (eg, <i>Enterococcus faecalis</i>), in combination with an aminoglycoside</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Staphylococcal:</i> Treatment of staphylococcal endocarditis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Streptococcal:</i> Treatment of endocarditis due to <i>Streptococcus viridans</i> or <i>Streptococcus bovis,</i> as monotherapy or in combination with an aminoglycoside</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Enterocolitis (oral): </b>Treatment of enterocolitis caused by <i>Staphylococcus aureus </i>(including methicillin-resistant strains). <b>Note:</b> Staphylococcal enterocolitis is uncommon; the disease and treatment are not well described in the literature (Iwata 2014; Lin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Staphylococcal infections (injection): </b>Treatment of serious or severe infections (eg, septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections) caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci; empiric therapy of infections when methicillin-resistant staphylococci are suspected</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708305\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Catheter-related infections; Cerebrospinal fluid (CSF) shunt infection; Community-acquired pneumonia (children); Clostridium difficile infection (adults; rectal administration); Endophthalmitis, treatment; Group B Streptococcus, maternal use (neonatal prophylaxis); Intra-abdominal infections; Meningitis, bacterial; Perioperative prophylaxis; Peritonitis, treatment (continuous ambulatory peritoneal dialysis [CAPD] patients); Prosthetic joint infection; Surgical-site infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233387\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV vancomycin may be confused with INVanz</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vancomycin may be confused with clindamycin, gentamicin, tobramycin, valACYclovir, vecuronium, Vibramycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233298\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%: Cardiovascular: Hypotension (accompanied by flushing)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Local phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Chills, drug fever</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Eosinophilia, neutropenia (reversible)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Frequency not defined: Hypersensitivity: Flushing of face and neck (Red man syndrome; may be infusion related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: DRESS syndrome (drug rash with eosinophilia and systemic symptoms), ototoxicity (rare; use of other ototoxic agents may increase risk), renal failure (limited data suggesting direct relationship), Stevens-Johnson syndrome, thrombocytopenia, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%: Gastrointestinal: Abdominal pain, dysgeusia (with oral solution), nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Diarrhea, flatulence, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: Increased serum creatinine, interstitial nephritis, ototoxicity, renal failure, renal insufficiency, thrombocytopenia, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233314\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vancomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233295\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation and thrombophlebitis: IV vancomycin is an irritant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Pain, tenderness, and necrosis may occur with extravasation. If thrombophlebitis occurs, slow infusion rates, dilute solution (eg, 2.5 to 5 g/L) and rotate infusion sites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: May cause nephrotoxicity although limited data suggest direct causal relationship; usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. If multiple sequential (&ge;2) serum creatinine concentrations demonstrate an increase of 0.5 mg/dL or &ge;50% increase from baseline (whichever is greater) in the absence of an alternative explanation, the patient should be identified as having vancomycin-induced nephrotoxicity (ASHP/IDSA/SIDP [Rybak 2009]). Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible. Nephrotoxicity has been reported following treatment with oral vancomycin (typically in patients &gt;65 years of age).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenia: Prolonged therapy and use of concomitant drugs that cause neutropenia may increase the risk; monitor leukocyte counts periodically in these patients. Prompt reversal of neutropenia is expected after discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ototoxicity: Ototoxicity is rarely associated with monotherapy. It has been most frequently reported in patients receiving excessive doses, those who have underlying hearing loss, or those receiving concomitant ototoxic drugs (eg, aminoglycosides). Serial auditory function testing may be helpful to minimize risk. Ototoxicity may be transient or permanent; discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile </i>infection (CDI); CDI has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inflammatory bowel disease: Clinically significant serum concentrations have been reported in patients with inflammatory disorders of the intestinal mucosa who have taken oral vancomycin (multiple doses) for the treatment of <i>C. difficile</i>-associated diarrhea. Although use may be warranted, the risk for adverse reactions may be higher in this situation; consider monitoring serum trough concentrations, especially with renal insufficiency, severe colitis, concurrent rectal vancomycin administration, and/or concomitant IV aminoglycosides. The Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) suggest that it is appropriate to obtain trough concentrations when a patient is receiving long courses of &ge;2 g/day in adults (SHEA/IDSA [Cohen 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment or those receiving other nephrotoxic or ototoxic drugs; dosage modification required (especially in elderly patients). Accumulation may occur after multiple oral doses of vancomycin in patients with renal impairment; consider monitoring trough concentrations in this circumstance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Oral vancomycin is only indicated for the treatment of CDI or enterocolitis due to <i>S. aureus</i> and is not effective for systemic infections; parenteral vancomycin is not effective for the treatment of enterocolitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Rapid IV administration (eg, over &lt;60 minutes) may result in hypotension, flushing, erythema, urticaria, pruritus and, rarely, cardiac arrest. Reactions usually cease promptly after infusion is stopped. Frequency of infusion reactions may increase with concomitant administration of anesthetics. If used in conjunction with anesthesia, complete the vancomycin infusion prior to anesthesia induction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraocular administration (off-label route): Hemorrhagic occlusive retinal vasculitis (HORV), including permanent visual loss, has been reported in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. Safety and efficacy of intraocularly administered vancomycin has not been established; vancomycin is not indicated for prophylaxis of endophthalmitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraperitoneal administration (off-label route): Use caution when administering intraperitoneally (IP); in some continuous ambulatory peritoneal dialysis (CAPD) patients, chemical peritonitis (cloudy dialysate, fever, severe abdominal pain) has occurred. Symptoms are self-limited and usually clear after vancomycin discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300205\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233300\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10037&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Vancomycin may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May diminish the therapeutic effect of Vancomycin. Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Vancomycin may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Vancomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Vancomycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperacillin: May enhance the nephrotoxic effect of Vancomycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233302\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (oral) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6833811\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Vancomycin crosses the placenta and can be detected in fetal serum, amniotic fluid, and cord blood (Bourget 1991; Reyes 1989). Adverse fetal effects, including sensorineural hearing loss or nephrotoxicity, have not been reported following maternal use during the second or third trimesters of pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The pharmacokinetics of vancomycin may be altered during pregnancy and pregnant patients may need a higher dose of vancomycin. Maternal half-life is unchanged, but the volume of distribution and the total plasma clearance may be increased (Bourget 1991). Individualization of therapy through serum concentration monitoring may be warranted. Vancomycin is recommended for the treatment of mild, moderate, or severe <i>Clostridium difficile</i> infections in pregnant women (ACG [Surawicz 2013]). Vancomycin is recommended as an alternative agent to prevent the transmission of group B streptococcal (GBS) disease from mothers to newborns (ACOG 2011; CDC 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233318\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Vancomycin is present in breast milk following IV administration. Vancomycin exhibits minimal oral absorption; therefore, the amount available to pass into the milk would be limited following oral administration and any amount present in breast milk is unlikely to reach the bloodstream of a breastfed infant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of vancomycin is 4.8% when calculated using the highest breast milk concentration located and compared to an infant therapeutic oral dose of 40 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Using the highest milk concentration (12.7 mcg/mL), the estimated daily infant dose via breast milk is 1.9 mg/kg/day. This milk concentration was obtained 4 hours after maternal administration of IV vancomycin 1 g every 12 hours; therapy had been initiated at least 1 week prior to milk sampling (Reyes 1989).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vancomycin is recommended for the treatment of mild, moderate, or severe <i>Clostridium difficile</i> infections in breastfeeding women (ACG [Surawicz 2013]). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233319\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233304\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intravenous: Periodic renal function tests, CBC; serum trough vancomycin concentrations in select patients (eg, aggressive dosing, life-threatening infection, seriously ill, unstable renal function, concurrent nephrotoxins, prolonged courses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suggested frequency of trough vancomycin concentration monitoring for intermittent infusion (ASHP/IDSA/SIDP [Rybak 2009]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hemodynamically stable patients:</i> Draw trough concentrations at least once-weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hemodynamically unstable patients:</i> Draw trough concentrations more frequently or in some instances daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prolonged courses (&gt;3 to 5 days):</i> Draw at least one steady-state trough concentration; repeat as clinically appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Drawing &gt;1 trough concentration prior to the fourth dose for short course (&lt;3 days) or lower intensity dosing (target trough concentrations &lt;15 mcg/mL) is not recommended. For patients with uncomplicated skin and soft tissue infections who are not obese and have normal renal function, serum trough monitoring is generally not needed (IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral/rectal therapy: Serum sample monitoring is not typically required; consider monitoring serum trough concentrations, especially with renal insufficiency, severe colitis, rectal vancomycin administration (SHEA/IDSA [Cohen 2010]), and/or concomitant IV aminoglycosides.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233307\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Timing of serum samples: Draw trough concentration just before the administration of a dose at steady-state conditions. Steady state conditions generally occur approximately after the third dose; therefore, may begin monitoring vancomycin trough concentrations before the fourth dose (usually within 1 hour of administration). More specific recommendations for timing of serum samples may be found in <b>Monitoring Parameters</b>. Drawing peak concentrations is no longer recommended (Alvarez 2016; ASHP/IDSA/SIDP [Rybak 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Therapeutic levels: Trough: &ge;10 mcg/mL. For pathogens with an MIC &le;1 mcg/mL, the minimum trough concentration should be 15 mcg/mL to meet target AUC/MIC of &ge;400 (see &quot;<b>Note</b>&quot; below). For complicated infections (eg, bacteremia, endocarditis, osteomyelitis, meningitis, and hospital-acquired pneumonia caused by <i>S. aureus</i>) or infections associated with severe sepsis or septic shock, trough concentrations of 15 to 20 mcg/mL are recommended to improve penetration and improve clinical outcomes (ASHP/IDSA/SIDP [Rybak 2009]; Liu 2011; Rhodes 2017). The American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guidelines for hospital-acquired pneumonia and the IDSA meningitis guidelines also recommend trough concentrations of 15 to 20 mcg/mL (Kalil 2016; Tunkel 2004; Tunkel 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Although AUC/MIC is the preferred pharmacokinetic-pharmacodynamic parameter used to determine clinical effectiveness, trough serum concentrations may be used as a surrogate marker for AUC and are recommended as the most accurate and practical method of vancomycin intermittent infusion monitoring (IDSA [Liu 2011]; ASHP/IDSA/SIDP [Rybak 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic: &gt;80 mcg/mL (SI: &gt;54 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraventricular (off-label route): Prior to administration of the next intraventricular dose, withdraw a sample of CSF. This trough CSF concentration divided by the vancomycin MIC for the isolated bacterial pathogen (inhibitory quotient) should exceed 10 to 20 (IDSA [Tunkel 2004; Tunkel 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233294\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by blocking glycopeptide polymerization through binding tightly to D-alanyl-D-alanine portion of cell wall precursor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233313\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Displays time-dependent antimicrobial killing; slowly bacteriocidal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Poor; Rectal: significant absorption through inflamed colonic mucosa may occur; Intraperitoneal (IP): 60% of an IP dose absorbed in 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes widely in body tissue and fluids, except for CSF</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonate, term: 0.57 to 0.69 L/kg (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates, receiving ECMO (mean age: ~39 weeks): Variable; 1.1 L/kg (range: 0.6 to 2.1 L/kg) (Amaker 1996); others have reported lower values: 0.45 &plusmn; 0.18 L/kg (Buck 1998), 0.67 &plusmn; 0.15 L/kg (Mulla 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients: Median: 0.57 L/kg (range: 0.26 to 1.05 L/kg) (Marsot 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.4 to 1 L/kg (ASHP/IDSA/SIDP [Rybak 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relative diffusion from blood into CSF: Good only with inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CSF concentrations: 0.2 to 17.3 mcg/mL (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CSF:blood level ratio: Normal meninges: Nil; Inflamed meninges: 7.1% to 68% (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Uninflamed meninges: 0 to 4 mcg/mL; serum concentration dependent (ASHP/IDSA/SIDP [Rybak 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Inflamed meninges: 6 to 11 mcg/mL; serum concentration dependent (ASHP/IDSA/SIDP [Rybak 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CSF:serum level ratio: Normal meninges: Nil; Inflamed meninges: ~80% (Shokouhi 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~55%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: No apparent metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Biphasic: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Newborns: 6 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates receiving ECMO: 6.53 &plusmn; 2.1 hours (Buck 1998); others have reported longer: 10.4 &plusmn; 6.7 hours (Mulla 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 3 months to 4 years: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &gt;3 years: 2.2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 4 to 6 hours; significantly prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): 7.5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IV: Immediately after completion of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily via glomerular filtration; IV: Urine (75% as unchanged drug in the first 24 hours); Oral: Primarily feces</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: presence of malignancy in children is associated with an increase in vancomycin clearance</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: 0.63 to 1.5 mL/minute/kg; dependent on GA and/or PMA (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates, receiving ECMO: ~0.79 mL/minute/kg (Amaker 1996; Buck 1998); others have reported a slightly slower rate: 0.67 mL/minute/kg (Mulla 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients: Median: 1.1 mL/minute/kg (range: 0.33 to 1.87 mL/minute/kg) (Marsot 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.71 to 1.31 mL/minute/kg (de Hoog 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233317\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vancocin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (20): $1,887.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (20): $3,480.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vancomycin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (20): $626.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (20): $1,154.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (First-Vancomycin 25 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (150 mL): $82.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (First-Vancomycin 50 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (210 mL): $133.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vancomycin HCl in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 5% (100 mL): $13.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/200ML 5% (200 mL): $36.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/250ML 5% (250 mL): $14.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25GM/250ML 5% (250 mL): $16.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/250ML 5% (250 mL): $22.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/500ML 5% (500 mL): $23.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/500ML 5% (500 mL): $22.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/500ML 5% (500 mL): $21.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 5% (100 mL): $7.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750MG/150ML 5% (150 mL): $13.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vancomycin HCl in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/150ML 0.9% (150 mL): $17.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/200ML 0.9% (200 mL): $28.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/250ML 0.9% (250 mL): $18.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25GM/150ML 0.9% (150 mL): $16.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25GM/250ML 0.9% (250 mL): $19.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/150ML 0.9% (150 mL): $18.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/250ML 0.9% (250 mL): $22.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/500ML 0.9% (500 mL): $23.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/250ML 0.9% (250 mL): $21.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/300ML 0.9% (300 mL): $26.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/500ML 0.9% (500 mL): $25.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/250ML 0.9% (250 mL): $22.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/500ML 0.9% (500 mL): $25.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5GM/500ML 0.9% (500 mL): $29.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.9% (100 mL): $8.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750MG/150ML 0.9% (150 mL): $13.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750MG/250ML 0.9% (250 mL): $14.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Firvanq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (150 mL): $113.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (150 mL): $150.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Vancomycin HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $255.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 g (1): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $3.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (1): $11.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (1): $7.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 mg (1): $95.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Vancomycin+SyrSpend SF PH4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (120 mL): $656.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233320\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adimicin (HR);</li>\n      <li>Aekovan (PH);</li>\n      <li>Celovan (HK);</li>\n      <li>Citerin (MX);</li>\n      <li>Covan (BD);</li>\n      <li>Covancin (IN);</li>\n      <li>Cytovan (IN);</li>\n      <li>Dhacocin (MY, SG);</li>\n      <li>Edicin (BG, CZ, EE, HR, RO, RU, SK, TH, TR, UA);</li>\n      <li>Estavam (MX);</li>\n      <li>Forstaf (IN);</li>\n      <li>Icoplax (AR, PE);</li>\n      <li>Kovan (CL);</li>\n      <li>Levovanox (IT);</li>\n      <li>Mersa (PH);</li>\n      <li>Normedia (SE);</li>\n      <li>Riveran (AR, PE);</li>\n      <li>Tancofeto (MY);</li>\n      <li>Vacsol (MX);</li>\n      <li>Vagran (VE);</li>\n      <li>Vamysin (BE);</li>\n      <li>Vanauras (MX);</li>\n      <li>Vanaurus (EC);</li>\n      <li>Vanbiotic (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vancard (BD);</li>\n      <li>Vancep (ID);</li>\n      <li>Vancin (BD);</li>\n      <li>Vancin-S (TH);</li>\n      <li>Vanco-SAAR (DE);</li>\n      <li>Vanco-Teva (IL);</li>\n      <li>Vancoavenir (IL);</li>\n      <li>Vancobac (BD);</li>\n      <li>Vancocid (TH);</li>\n      <li>Vancocin (AE, AT, AU, BB, BG, EG, HU, IE, JO, LK, MT, NL, RU, SA, SI, VN, ZA);</li>\n      <li>Vancocin CP (AU, CN, IN, MX, PK, TW);</li>\n      <li>Vancocin HCl (BF, BJ, CH, CI, DK, ET, GB, GH, GM, GN, HK, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, SC, SD, SE, SL, SN, TN, TW, TZ, UG, ZM, ZW);</li>\n      <li>Vancocina (IT);</li>\n      <li>Vancocine (FR);</li>\n      <li>Vancodex (ID);</li>\n      <li>Vancoled (AE, EG, KR, KW, VN);</li>\n      <li>Vancolon (AE, BH, ET, KW, LB, PH, QA, SA);</li>\n      <li>Vancomax (PE, PY);</li>\n      <li>Vancomet (PH);</li>\n      <li>Vancomicina (DO);</li>\n      <li>Vanconix (BD);</li>\n      <li>Vancorin (TR);</li>\n      <li>Vancorus (RU);</li>\n      <li>Vancosam (LK);</li>\n      <li>Vancosan (BR, FI, IS, LT, LV);</li>\n      <li>Vancotech (LK);</li>\n      <li>Vancotek (AR);</li>\n      <li>Vancotex (MY);</li>\n      <li>Vancotrat (BR);</li>\n      <li>Vancox (MX);</li>\n      <li>Vancozin (KR);</li>\n      <li>Vanlyo (TW);</li>\n      <li>Vanmicira (CZ);</li>\n      <li>Vantocil (ID);</li>\n      <li>Varedet (AR, PE, PY, UY);</li>\n      <li>Voncon (GR);</li>\n      <li>Vondem (GR);</li>\n      <li>Voxin (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramowicz M. Antimicrobial prophylaxis in surgery. <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy.</i> 16th ed, New York, NY: Medical Letter, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahkee S, Smith R, Ritter GW. Once-daily aminoglycoside dosing in lower respiratory tract infections. <i>Pharm Therapeut.</i> 1995,20:226-234.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26856841\"></a>&Aacute;lvarez R, L&oacute;pez Cort&eacute;s LE, Molina J, Cisneros JM, Pach&oacute;n J. Optimizing the clinical use of vancomycin. <i>Antimicrob Agents Chemother</i>. 2016;60(5):2601-2609. doi: 10.1128/AAC.03147-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/26856841/pubmed\" target=\"_blank\" id=\"26856841\">26856841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of Vancomycin in Critically Ill Infants Undergoing Extracorporeal Membrane Oxygenation. <i>Antimicrob Agents Chemother.</i> 1996;40(5):1139-1142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/8723454/pubmed\" target=\"_blank\" id=\"8723454\">8723454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases. Treatment of bacterial meningitis. <i>Pediatrics.</i> 1988;81(6):904-907.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/3368290/pubmed\" target=\"_blank\" id=\"3368290\">3368290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns. <i>Obstet Gynecol.</i> 2011;117(4):1019-1027.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/21422882/pubmed\" target=\"_blank\" id=\"21422882\">21422882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson DJ, Podgorny K, Berr&iacute;os-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. <i>Infect Control Hosp Epidemiol</i>. 2014;35(6):605-627. doi: 10.1086/676022.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/24799638/pubmed\" target=\"_blank\" id=\"24799638\">24799638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive Intracolonic Vancomycin for Severe <i>Clostridium difficile </i>Colitis: Case Series and Review of the Literature. C<i>lin Infect Dis.</i> 2002;35(6):690-696.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/12203166/pubmed\" target=\"_blank\" id=\"12203166\">12203166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary: <i>Endorsed by the Infectious Diseases Society of America</i>,&rdquo; <i>Circulation</i>, 2005, 111(23):3167-184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/15956145/pubmed\" target=\"_blank\" id=\"15956145\">15956145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benner KW, Worthington MA, Kimberlin DW, Hill K, Buckley K, Tofil NM. Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review. <i>J Pediatr Pharmacol Ther</i>. 2009;14(2):86-93. doi: 10.5863/1551-6776-14.2.86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/23055895/pubmed\" target=\"_blank\" id=\"23055895\">23055895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari E, Baddour LM. Prosthetic joint infection: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berr&iacute;os-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. <i>JAMA Surg</i>. 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/28467526/pubmed\" target=\"_blank\" id=\"28467526\">28467526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Delouis C, et al, &quot;Transplacental Passage of Vancomycin During the Second Trimester of Pregnancy,&quot; <i>Obstet Gynecol</i>, 1991, 78(5 Pt 2):908-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/1923224/pubmed\" target=\"_blank\" id=\"1923224\">1923224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buck ML, &quot;Vancomycin Pharmacokinetics in Neonates Receiving Extracorporeal Membrane Oxygenation,&quot; <i>Pharmacotherapy</i>, 1998, 18(5):1082-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/9758319/pubmed\" target=\"_blank\" id=\"9758319\">9758319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burkhart KK, Metcalf S, Shurnas E, et al, &ldquo;Exchange Transfusion and Multidose Activated Charcoal Following Vancomycin Overdose,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1992, 30(2):285-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/1588677/pubmed\" target=\"_blank\" id=\"1588677\">1588677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler M, Olson A, Drekonja D, et al; Agency for Healthcare Research and Quality (US). Early diagnosis, prevention, and treatment of <i>Clostridium difficile</i>: update [Internet]. 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/27148613/pubmed\" target=\"_blank\" id=\"27148613\">27148613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cant&uacute; TG, Yamanaka-Yuen NA, and Lietman PS, &ldquo;Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value,&rdquo; <i>Clin Infect Dis</i>, 1994, 18(4):533-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/8038306/pubmed\" target=\"_blank\" id=\"8038306\">8038306</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-10):1-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Recommendations for Preventing the Spread of Vancomycin Resistance - Recommendations of the Hospital Infection Control Practice Advisory Committee (HICPAC),&rdquo; <i>MMWR Recomm Rep</i>, 1995, 44(RR-12):1-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chang D, Liem L, and Malogolowkin M, &ldquo;A Prospective Study of Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients,&rdquo; <i>Pediatr Infect Dis J</i>, 1994, 13(11):969-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7845750/pubmed\" target=\"_blank\" id=\"7845750\">7845750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chang D, &ldquo;Influence of Malignancy on the Pharmacokinetics of Vancomycin in Infants and Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(8):667-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/8532423/pubmed\" target=\"_blank\" id=\"8532423\">8532423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen SH, Gerding DN, Johnson S, et al, &ldquo;Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA), <i>Infect Control Hosp Epidemiol</i>, 2010, 31(5):431-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/20307191/pubmed\" target=\"_blank\" id=\"20307191\">20307191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunha BA, &ldquo;Vancomycin,&rdquo; <i>Med Clin North Am</i>, 1995, 79(4):817-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7791425/pubmed\" target=\"_blank\" id=\"7791425\">7791425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cutler NR, Narang PK, Lesko LJ, et al, &ldquo;Vancomycin Disposition: The Importance of Age,&rdquo; <i>Clin Pharmacol Ther</i>, 1984, 36(6):803-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/6499360/pubmed\" target=\"_blank\" id=\"6499360\">6499360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3752110\"></a>Das Gupta V, Stewart KR, Nohria S. Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections. <i>Am J Hosp Pharm</i>. 1986;43(7):1729-1731.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/3752110/pubmed\" target=\"_blank\" id=\"3752110\">3752110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15139793\"></a>de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. <i>Clin Pharmacokinet.</i> 2004;43(7):417-440.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/15139793/pubmed\" target=\"_blank\" id=\"15139793\">15139793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. <i>Clin Microbiol Infect</i>. 2014;20(suppl 2):1-26. doi: 10.1111/1469-0691.12418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/24118601/pubmed\" target=\"_blank\" id=\"24118601\">24118601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeVries E, van Rossum MAJ, Garritsen EJA, et al, &ldquo;No Difference in Frequency of Adverse Reactions to Either Vancomycin or Teicoplanin in 70 Pediatric Bone Marrow Transplant Patients,&rdquo; <i>Bone Marrow Transplant</i>, 1995, 15(Suppl 2):124.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drew RH, Sakoulas G. Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duffull SB and Begg EJ, &ldquo;Vancomycin Toxicity. What Is the Evidence for Dose Dependency?&rdquo; <i>Adverse Drug React Toxicol Rev</i>, 1994, 13(2):103-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7918897/pubmed\" target=\"_blank\" id=\"7918897\">7918897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durand M. Bacterial endophthalmitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards FH, Engelman RM, Houck P, et al, &ldquo;The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration,&rdquo; <i>Ann Thorac Surg</i>, 2006, 81(1):397-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/16368422/pubmed\" target=\"_blank\" id=\"16368422\">16368422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engelman R, Shahian D, Shemin R, et al, &ldquo;The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice,&rdquo; <i>Ann Thorac Surg</i>, 2007, 83(4):1569-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/17383396/pubmed\" target=\"_blank\" id=\"17383396\">17383396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Firvanq (vancomycin hydrochloride) [prescribing information]. Wilmington, MA: CutisPharma; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    File TM Jr. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French GL, &ldquo;Enterococci and Vancomycin Resistance,&rdquo; <i>Clin Infect Dis</i>, 1998, 27(Suppl 1):75-83.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frimat L, Hestin D, Hanesse B, et al, &ldquo;Acute Renal Failure Due to Vancomycin Alone,&rdquo; <i>Nephrol Dial Transplant</i>, 1995, 10(4):550-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7624002/pubmed\" target=\"_blank\" id=\"7624002\">7624002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. <i>Pediatr Infect Dis J</i>. 2009;28(5):398-402. doi: 10.1097/INF.0b013e3181906e40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/19295465/pubmed\" target=\"_blank\" id=\"19295465\">19295465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11673290\"></a>Gan IM, van Dissel JT, Beekhuis H, et al, &ldquo;Intravitreal Vancomycin and Gentamicin Concentrations in Patients With Postoperative Endophthalmitis,&rdquo; <i>Br J Ophthalmol</i>, 2001, 85(11):1289-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/11673290/pubmed\" target=\"_blank\" id=\"11673290\">11673290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geissmann C, Beylot-Barry M, Doutre M-S, et al, &ldquo;Drug-Induced Linear IgA Bullous Dermatosis,&rdquo; <i>J Am Acad Dermatol</i>, 1995, 32(2 Pt 1):296.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Generali JA, Cada DA. &ldquo;Off-Label Drug Uses: Vancomycin (Rectal): <i>Clostridium difficile</i> infection (Severe/Complicated),&rdquo; <i>Hosp Pharm</i>, 2011, 46(5):327-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, Moellering RC, Eliopoulos GM, et al, eds, <i>The Sanford Guide To Antimicrobial Therapy</i>, 36th ed, Hyde Park, VT: Antimicrobial Therapy, Inc, 2006, 6-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldenberg DL, Sexton DL. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golightly LK, Teitelbaum I, Kiser TH, et al. (eds.) <i>Renal Pharmacotherapy</i>. Springer Science, New York. 2013</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al; Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother.</i> 2012;67(2):269-289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <i>Eur Heart J</i>. 2015;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/26320109/pubmed\" target=\"_blank\" id=\"26320109\">26320109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and &quot;red man syndrome&quot;: comparison of 1- and 2-hour infusions. <i>Antimicrob Agents Chemother</i>. 1990;34(4):550-554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/1693055/pubmed\" target=\"_blank\" id=\"1693055\">1693055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill LM, &ldquo;Fetal Distress Secondary to Vancomycin-Induced Maternal Hypotension,&rdquo; <i>Am J Obstet Gynecol</i>, 1985, 153(1):74-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/4037001/pubmed\" target=\"_blank\" id=\"4037001\">4037001</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iwata K, Doi A, Fukuchi T, et al. A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant Staphylococcus aureus. <i>BMC Infect Dis.</i> 2014;14:247-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/24884581/pubmed\" target=\"_blank\" id=\"24884581\">24884581</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joy MS, Matzke GR, Frye RF, et al, &ldquo;Determinants of Vancomycin Clearance by Continuous Veno-Venous Hemofiltration and Continuous Veno-Venous Hemodialysis,&rdquo; <i>Am J Kidney Dis</i>, 1998, 31(6):1019-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/9631848/pubmed\" target=\"_blank\" id=\"9631848\">9631848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly CP. Clostridium difficile in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly CP, Pothoulakis C, and LaMont JT, &ldquo;<i>Clostridium difficile</i> colitis,&rdquo; <i>N Engl J Med</i>, 1994, 330(4):257-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/8043060/pubmed\" target=\"_blank\" id=\"8043060\">8043060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelsey SF, David M, Doft BH, et al, &ldquo;Results of the Endophthalmitis Vitrectomy Study. A Randomized Trial of Immediate Vitrectomy and of Intravenous Antibiotics for the Treatment of Postoperative Bacterial Endophthalmitis. Endophthalmitis Vitrectomy Study Group,&rdquo; <i>Arch Ophthalmol</i>, 1995, 113(12):1479-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7487614/pubmed\" target=\"_blank\" id=\"7487614\">7487614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Brady MT, Jackson MA, Long SS, eds; Committee on Infectious Diseases; American Academy of Pediatrics. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. <i>Nephrol Dial Transplant</i>. 2007;22(8):2239-2246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/17403700/pubmed\" target=\"_blank\" id=\"17403700\">17403700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12225605\"></a>Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. <i>Crit Care</i>. 2002;6(4):313-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/12225605/pubmed\" target=\"_blank\" id=\"12225605\">12225605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leader WG, Chandler MH, and Castiglia M, &ldquo;Pharmacokinetic Optimization of Vancomycin Therapy,&rdquo; <i>Clin Pharmacokinet</i>, 1995, 28(4):327-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7648760/pubmed\" target=\"_blank\" id=\"7648760\">7648760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard MB, Koren G, Stevenson DK, et al, &ldquo;Vancomycin Pharmacokinetics in Very Low Birth Weight Neonates,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(5):282-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/2657617/pubmed\" target=\"_blank\" id=\"2657617\">2657617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li PK, Szeto CC, Piraino B, et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. <i>Perit Dial Int</i>. 2016;36(5):481-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/27282851/pubmed\" target=\"_blank\" id=\"27282851\">27282851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin Z, Kotler DP, Schlievert PM, Sordillo EM. Staphylococcal entercolitis: forgotten but not gone? <i>Dig Dis Sci</i>. 2010;55(5):1200-1207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/19609675/pubmed\" target=\"_blank\" id=\"19609675\">19609675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linden P, &ldquo;Antibiotic Therapy in Critical Illness,&rdquo; <i>Multidisciplinary Critical Care Review</i>, Zimmerman JL and Roberts PR, eds, Des Plaines, IL: Society of Critical Care Medicine, 2003,192.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus Aureus</i> Infections in Adults and Children: Executive Summary,&rdquo; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8364278\"></a>Luer MS and Hatton J, &ldquo;Vancomycin Administration Into the Cerebrospinal Fluid: A Review,&rdquo; <i>Ann Pharmacother</i>, 1993, 27(7-8):912-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/8364278/pubmed\" target=\"_blank\" id=\"8364278\">8364278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lundstrom TS and Sobel JD, &ldquo;Vancomycin, Trimethoprim-Sulfamethoxazole, and Rifampin,&rdquo; <i>Infect Dis Clin North Am</i>, 1995, 9(3):747-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7490442/pubmed\" target=\"_blank\" id=\"7490442\">7490442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyon GD and Bruce DL, &ldquo;Diphenhydramine Reversal of Vancomycin-Induced Hypotension,&rdquo; <i>Anesth Analg</i>, 1988, 67(11):1109-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/3189903/pubmed\" target=\"_blank\" id=\"3189903\">3189903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(suppl 2):s27-s72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of population pharmacokinetic analyses. <i>Clin Pharmacokinet.</i> 2012;51(1):1-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/22149255/pubmed\" target=\"_blank\" id=\"22149255\">22149255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute; R, Rosell M, Pou L, et al, &ldquo;Influence of Biochemical Parameters of Liver Function on Vancomycin Pharmacokinetics,&rdquo; <i>Pharmacol Toxicol</i>, 1996, 79(2):55-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/8878246/pubmed\" target=\"_blank\" id=\"8878246\">8878246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matzke GR, Zhanel GG, and Guay DRP, &ldquo;Clinical Pharmacokinetics of Vancomycin,&rdquo; <i>Clin Pharmacokinet</i>, 1986, 11(4):257-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/3530582/pubmed\" target=\"_blank\" id=\"3530582\">3530582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2009, 49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morris JG Jr, Shay DK, Hebden JN, et al, &ldquo;Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin. Establishment of Endemicity in a University Medical Center,&rdquo; <i>Ann Intern Med</i>, 1995, 123(4):250-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7611590/pubmed\" target=\"_blank\" id=\"7611590\">7611590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60(3):265-275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/16120065/pubmed\" target=\"_blank\" id=\"16120065\">16120065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy J. <i>Clinical Pharmacokinetics</i>. 5th ed. Bethesda, MD: American Society of Health-System Pharmacists Inc; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray BE, &ldquo;Vancomycin-Resistant Enterococcal Infections,&rdquo; <i>N Engl J Med</i>, 2000, 342(10):710-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/10706902/pubmed\" target=\"_blank\" id=\"10706902\">10706902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray BE, Arias CA, Nannini EC. Glycopeptides (Vancomycin and Teicoplanin), Steptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin). In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th ed, Bennett JE, Dolin R, Blaser MJ (Eds), Elsevier Saunders, Philadelphia 2015. p.377.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nielsen HE, Sorensen I, and Hansen HE, &ldquo;Peritoneal Transport of Vancomycin During Peritoneal Dialysis,&rdquo; <i>Nephron</i>, 1979, 24(6):274-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/514426/pubmed\" target=\"_blank\" id=\"514426\">514426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng K, Mabasa VH, Chow I, Ensom MH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. <i>Neurocrit Care</i>. 2014;20(1):158-171. doi: 10.1007/s12028-012-9784-z.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/23090839/pubmed\" target=\"_blank\" id=\"23090839\">23090839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onwuchuruba CN, Towers CV, Howard BC, Hennessy MD, Wolfe L, Brown MS. Transplacental passage of vancomycin from mother to neonate. <i>Am J Obstet Gynecol</i>. 2014;210(4):352.e1-352.e4. doi: 10.1016/j.ajog.2014.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/24679944/pubmed\" target=\"_blank\" id=\"24679944\">24679944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21782382\"></a>Packer M, Chang DF, Dewey SH, et al, &ldquo;Prevention, Diagnosis, and Management of Acute Postoperative Bacterial Endophthalmitis,&rdquo; <i>J Cataract Refract Surg</i>, 2011, 37(9):1699-1714.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/21782382/pubmed\" target=\"_blank\" id=\"21782382\">21782382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27226704\"></a>Patel T, Lewis ME, Niesley ML, Chowdhury M. Postneurosurgical Central Nervous System Infection Due to Enterococcus faecalis Successfully Treated With Intraventricular Vancomycin. <i>Infect Dis Clin Pract (Baltim Md)</i>. 2016;24(3):174-176.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/27226704/pubmed\" target=\"_blank\" id=\"27226704\">27226704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quagliarello VJ and Scheld WM, &ldquo;Treatment of Bacterial Meningitis,&rdquo; <i>N Engl J Med</i>, 1997, 336(10):708-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/9041103/pubmed\" target=\"_blank\" id=\"9041103\">9041103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reardon J, Lau TT, Ensom MH. Vancomycin loading doses: a systematic review. <i>Ann Pharmacother</i>. 2015;49(5):557-565. doi: 10.1177/1060028015571163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/25712445/pubmed\" target=\"_blank\" id=\"25712445\">25712445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Results of the Endophthalmitis Vitrectomy Study. A Randomized Trial of Immediate Vitrectomy and of Intravenous Antibiotics for the Treatment of Postoperative Bacterial Endophthalmitis. Endophthalmitis Vitrectomy Study Group,&rdquo; <i>Arch Ophthalmol</i>, 1995, 113(12):1479-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7487614/pubmed\" target=\"_blank\" id=\"7487614\">7487614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reyes MP and Ostrea EM Jr, &quot;Toxicity of Vancomycin Given During Pregnancy (Reply),&quot; <i>Am J Obstet Gynecol</i>, 1990, 163(4 Pt 1):1376.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reyes MP, Ostrea EM Jr, Cabinian AE, et al, &quot;Vancomycin During Pregnancy: Does It Cause Hearing Loss or Nephrotoxicity in the Infant?&quot; <i>Am J Obstet Gynecol</i>, 1989, 161(4):977-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/2801848/pubmed\" target=\"_blank\" id=\"2801848\">2801848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodvold KA, Everett JA, Pryka RD, and Kraus DM, &ldquo;Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children,&rdquo; Clin Pharmacokinet, 1997, 33(1):32-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/3415206/pubmed\" target=\"_blank\" id=\"3415206\">3415206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. <i>Clin Infect Dis</i>. 2015;61(6):934-941. doi: 10.1093/cid/civ409.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/26024909/pubmed\" target=\"_blank\" id=\"26024909\">26024909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roth DB and Flynn HW Jr, &ldquo;Antibiotic Selection in the Treatment of Endophthalmitis: The Significance of Drug Combinations and Synergy,&rdquo; <i>Surv Ophthalmol</i>, 1997, 41(5):395-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/9163836/pubmed\" target=\"_blank\" id=\"9163836\">9163836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rybak MJ, Albrecht LM, Boike SC, et al, &ldquo;Nephrotoxicity of Vancomycin, Alone and With an Aminoglycoside,&rdquo; <i>J Antimicrob Chemother</i>, 1990, 25(4):679-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/2351627/pubmed\" target=\"_blank\" id=\"2351627\">2351627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rybak MJ, Boike SC. Monitoring vancomycin therapy. <i>Drug Intell Clin Pharm</i>. 1986;20(10):757-761.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/3769763/pubmed\" target=\"_blank\" id=\"3769763\">3769763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rybak M, Lomaestro B, Rotschafer JC, et al, &ldquo;Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,&rdquo; <i>Am J Health-Syst Pharm</i>, 2009, 66(1):82-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/19106348/pubmed\" target=\"_blank\" id=\"19106348\">19106348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenfeld LA and Pote HH Jr, &ldquo;Diarrhea Associated With Parenteral Vancomycin Therapy,&rdquo; <i>Clin Infect Dis</i>, 1995, 20(6):1578-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/7548526/pubmed\" target=\"_blank\" id=\"7548526\">7548526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24973553\"></a>Shokouhi S, Alavi Darazam I. Determination of vancomycin trough level in serum and cerebrospinal fluid of patients with acute community-acquired meningitis: a prospective study. <i>J Infect</i>. 2014;69(5):424-429. doi: 10.1016/j.jinf.2014.06.010<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/24973553/pubmed\" target=\"_blank\" id=\"24973553\">24973553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20034345\"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis. </i> 2010;50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of <i>Clostridium difficile</i> infections. <i>Am J Gastroenterol</i>. 2013;108(4):478-498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/23439232 /pubmed\" target=\"_blank\" id=\"23439232 \">23439232 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szymusiak-Mutnick BA, Ross MB. Minimizing the occurrence of red-man syndrome. <i>Am J Health Syst Pharm</i>. 1996;53(17):2098.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/8870903/pubmed\" target=\"_blank\" id=\"8870903\">8870903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41:1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis [published online ahead of print February 14, 2017]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/28203777/pubmed\" target=\"_blank\" id=\"28203777\">28203777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed July 11, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vancomycin hydrochloride injection [prescribing information]. Cherry Hill, NJ: Samson Medical Technologies; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22915464\"></a>Verrall AJ, Llorin R, Tam VH, et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. <i>J Antimicrob Chemother</i>. 2012;67(12):2970-2973. doi: 10.1093/jac/dks328.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/22915464/pubmed\" target=\"_blank\" id=\"22915464\">22915464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. <i>J Clin Pharm Ther</i>. 2015;40(3):259-265. doi: 10.1111/jcpt.12270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/25865426/pubmed\" target=\"_blank\" id=\"25865426\">25865426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11157921\"></a>Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. <i>J Antimicrob Chemother</i>. 2001;47(2):246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/11157921/pubmed\" target=\"_blank\" id=\"11157921\">11157921</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilhelm MP, &ldquo;Vancomycin,&rdquo; <i>Mayo Clin Proc</i>, 1991, 66(11):1165-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/1943250/pubmed\" target=\"_blank\" id=\"1943250\">1943250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilhem MP, Estes L. Symposium on antimicrobial agents--Part XII. Vancomycin. <i>Mayo Clin Proc</i>, 1999; 74(9):928-935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/10488798/pubmed\" target=\"_blank\" id=\"10488798\">10488798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10037 Version 244.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50667383\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F233330\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233331\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F233378\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F233334\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F233358\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F233335\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F233336\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14320791\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233306\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F233291\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F45040033\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51063159\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F233311\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F233310\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25708305\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F233387\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233298\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233314\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233295\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300205\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233300\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233302\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6833811\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F233318\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F233319\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F233304\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F233307\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233294\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F233313\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F233317\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F233320\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10037|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vancomycin-patient-drug-information\" class=\"drug drug_patient\">Vancomycin: Patient drug information</a></li><li><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin: Pediatric drug information</a></li></ul></div></div>","javascript":null}